Calliditas Therapeutics AB Current Cash

Calliditas Therapeutics AB posts a current cash of $5.9M as of May 2026. That compares with $220K in the prior-year period — up 2577.3% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Calliditas Therapeutics AB's current cash was $220K. The latest reading is $5.9M — a 2577.3% year-over-year increase (period ending May 2026). Use the history and growth charts on this page for a longer lookback.

Current Cash is one piece of Calliditas Therapeutics AB's financial statement story. At $5.9M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CALT's current cash usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Calliditas Therapeutics AB's other metric pages and overview cover the third.

Judging Calliditas Therapeutics AB against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in current cash easier to interpret. Start with $5.9M here, then scan peer and history charts to see if the gap is persistent.